Cytokines and its Connection with Depression (Essay Sample)

Anxiety and Depression
Author
Institution Affiliation
Course
Instructor
Due Date
Hypothesis Review Supported with Evidence.
Recent studies have suggested that cytokines might have a causative relationship with depression. This hypothesis is hinged on the following observations: Patients treated with cytokines manifest symptoms of depression. Patients suffering from depression have an immune system that is activated. Medical disorders that occur as a result of a dysfunctional immune system tend to be depression. The hypothalamo-pituitary-adreno cortical axis, which is primarily active in depressed patients, can be triggered by cytokines. Cerebral noradrenergic systems activated by particular cytokines are common in patients with depression. Serotonergic rain systems have a significant impact on clinical depression and treatment. Stimulation of the immune response and injection of endotoxin (LPS) or interleukin-1 (IL-1) into animals causes sickness behavior that reflects depression, and regular antidepressant therapy is shown to inhibit LPS-induced sickness behavior (Maes et al., 2012).
The connection between cytokines and depression is built on facts supporting the assumptions above at varying intensity levels. In biological psychiatry, the relationship between immune alterations and depressive symptoms has been extensively researched, and it is one of the main diagnostic pillars of psychoneuroimmunology. Indications of immune activation are linked with depression. The initial optimism about the notion of immunosuppression relating to mental illness has given impetus to a much more balanced perspective. As a result, depressive individuals' immune systems are similar in function, with certain parts vanquished while others are stimulated. Any of the immunity changes found in patients who are depressed have also been documented in individuals with other psychological disorders. However, the precision of these modifications is indeed not exhaustive (Maes et al., 2012).
The effects of cytokine antagonists on depressive symptoms were examined. One of these hypotheses is cytokines' role in triggering depression (Sharpley & Agnew, 2011). Their brain antagonists have antidepressant properties. More general cytokine antagonists (which restrict the production of a few pro-inflammatory cytokines by enabling monocytes) are best adapted for such a task than the more particular cytokine antagonists. Therapeutic trials examining the potential impact of main-acting anti-inflammatory substances on depression should be conducted at the clinical level. Researchers observed nonspecific neuropsychiatric signs, some of which were linked to